Citi raised the firm’s price target on Genpact to $36 from $35 and keeps a Neutral rating on the shares. The analyst also opened a “30-day negative catalyst watch” on the shares. The firm expects Genpact to provide an initial 2024 outlook that is both well below its prior medium-term targets as well as below consensus expectations. The stock could react negatively to this setup and remain rangebound, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on G:
- Genpact just downgraded at Baird, here’s why
- Genpact downgraded to Neutral from Outperform at Baird
- Genpact names Krista Bessinger Head of Investor Relations, Caitlin Blewett CMO
- Genpact management to meet with Needham
- Genpact, AWS collaborate to redefine insurance claims lifecycle
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue